Valproic acid downregulates NF-κB p50 activity and IRAK-1 in a progressive thyroid carcinoma cell line

Hormone and Metabolic Research

Volumn 46, Issue 3, 2014, Pages 181-186

  Schwertheim, S ^a   Worm, K ^a   Schmid, K W ^a   Sheu Grabellus, S Y ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

BHT 101; chemoresistance; histone deacetylase inhibitor; radioresistance

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN P50; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MESSENGER RNA; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; CARCINOMA CELL; CELL STRAIN BHT 101; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA;

CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTERLEUKIN-6; INTERLEUKIN-8; NF-KAPPA B; PHOSPHORYLATION; RNA, MESSENGER; THYROID NEOPLASMS; UP-REGULATION; VALPROIC ACID;

EID: 84895543154     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1367043     Document Type: Article

References (43)

1. DeLellis R. A., Williams E. D. Tumours of the Thyroid and Parathyroid. In: DeLellis R. A., Lloyd R. V., Heitz P. U., Eng C. (ed.) World Health Organization Classification of Tumours, Pathology & Genetics, Tumours of Endocrine Organs. Lyon IARC Press: 2004; 49 133
2. Schmid K. W., Sheu S. Y., Tötsch M., Görges R., Bockisch A., Mann K. Pathologie des Schilddrüsenkarzinoms. Der Onkologe: 2005; 11 29 39
3. Blaheta R. A., Michaelis M., Driever P. H., Cinatl J. Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev: 2005; 25 383 397
4. Cinatl J. Jr, Cinatl J., Scholz M., Driever P. H., Henrich D., Kabickova H., Vogel J. U., Doerr H. W., Kornhuber B. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anti-cancer Drugs: 1996; 7 766 773
5. Driever P. H., Knüpfer M. M., Cinatl J., Wolff JE A. Valproic acid for the treatment of pediatric malignant glioma Valproinsäure zur Behandlung maligner Gliome im Kindesalter. Klin Padiatr: 1999; 211 323 328
6. Knüpfer M. M., Hernaiz-Driever P., Poppenborg H., Wolff JE A., Cinatl J. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res: 1998; 18 3585 3589
7. Michaelis M., Doerr H. W., Cinatl J. Valproic acid as anti-cancer drug. Current Pharmaceut Des: 2007; 13 3378 3393
8. Catalano M. G., Fortunati N., Pugliese M., Costantino L., Poli R., Bosco O., Boccuzzi G. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab: 2005; 90 1383 1389
9. Fortunati N., Catalano M. G., Arena K., Brignardello E., Piovesan A., Boccuzzi G. Valproic acid induces the expression of the Na+/I-symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab: 2004; 89 1006 1009
10. Noguchi H., Yamashita H., Murakami T., Hirai K., Noguchi Y., Maruta J., Yokoi T., Noguchi S. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J: 2009; 56 245 249
11. Shen W. T., Wong T. S., Chung W. Y., Wong M. G., Kebebew E., Duh Q. Y., Clark O. H. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery: 2005; 138 979 985
12. Chateauvieux S., Morceau F., Dicato M., Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol: 2010; 2010 1 18
13. Lagneaux L., Gillet N., Stamatopoulos B., Delforge A., Dejeneffe M., Massy M., Meuleman N., Kentos A., Martiat P., Willems L. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol: 2007; 35 1527 1537
14. Neri P., Tagliaferri P., Di Martino M. T., Calimeri T., Amodio N., Bulotta A., Ventura M., Eramo P. O., Viscomi C., Arbitrio M. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol: 2008; 143 520 531
15. Li X., Abdel-Mageed A. B., Mondal D., Kandil E. The Nuclear Factor Kappa-B Signaling Pathway as a Therapeutic Target Against Thyroid Cancers. Thyroid: 2013; 23 209 218
16. Mercurio F., Manning A. M. NF-kappaB as a primary regulator of the stress response. Oncogene: 1999; 18 6163 6171
17. Pacifico F., Mauro C., Barone C., Crescenzi E., Mellone S., Monaco M., Chiappetta G., Terrazzano G., Liguoro D., Vito P. Oncogenic and anti-apoptotic activity of NF-kB in human thyroid carcinomas. J Biol Chem: 2004; 279 54610 54619
18. Visconti R., Cerutti J., Battista S., Fedele M., Trapasso F., Zeki K., Miano M. P., de Nigris F., Casalino L., Curcio F. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene: 1997; 15 1987 1994
19. Li F., Sethi G. Targeting transcription factor NF-kB to overcome chemoresistance and radioresistance in cancer therapy. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer: 2010; 1805 167 180
20. Pályi I., Péter I., Daubner D., Vincze B., Lõrincz I. Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows Archiv B Cell Pathol Zell-Pathol: 1993; 63 263 269
21. Bhaumik D., Scott G. K., Schokrpur S., Patil C. K., Campisi J., Benz C. C. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene: 2008; 27 5643 5647
22. Taganov K. D., Boldin M. P., Chang K. J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA: 2006; 103 12481 12486
23. Chen Y. T., Kitabayashi N., Zhou X. K., Fahey T. J., Scognamiglio T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol: 2008; 21 1139 1146
24. He H., Jazdzewski K., Li W., Liyanarachchi S., Nagy R., Volinia S., Calin G. A., Liu C., Franssila K., Suster S., Kloos R. T., Croce C. M., De La Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA: 2005; 102 19075 19080
25. Nikiforova M. N., Tseng G. C., Steward D., Diorio D., Nikiforov Y. E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab: 2008; 93 1600 1608
26. Schwertheim S., Sheu S. Y., Worm K., Grabellus F., Schmid K. W. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res: 2009; 41 475 481
27. Sheu S. Y., Vogel E., Worm K., Grabellus F., Schwertheim S., Schmid K. W. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. Histopathology: 2010; 56 632 640
28. Abdul M., Hoosein N. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Res: 2001; 21 2045 2048
29. Go H. S., Seo J. E., Kim K. C., Han S. M., Kim P., Kang Y. S., Han S. H., Shin C. Y., Chang C. C., Chang C. Y. Valproic acid inhibits neural progenitor cell death by activation of NF-kappaB signaling pathway and up-regulation of Bcl-XL. J Biomed Sci: 2011; 18 48
30. Ichiyama T., Okada K., Lipton J. M., Matsubara T., Hayashi T., Furukawa S. Sodium valproate inhibits production of TNF-[alpha] and IL-6 and activation of NF-[kappa] B. Brain Res: 2000; 857 246 251
31. Rao J. S., Bazinet R. P., Rapoport S. I., Lee H. J. Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kB DNA binding activity and COX 2 mRNA1. Bipol Disord: 2007; 9 513 520
32. Galimberti S., Canestraro M., Savli H., Palumbo G. A., Tibullo D., Baaa N., Piaggi S., Guerrini F., Cine N., Metelli M. R. ITF2357 Interferes with Apoptosis and Inflammatory Pathways in the HL-60 Model: A Gene Expression Study. Anticancer Res: 2010; 30 4525 4536
33. LaBonte M., Wilson P., Fazzone W., Groshen S., Lenz H. J., Ladner R. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genom: 2009; 2 67
34. Li Y., Alam H. B. Modulation of Acetylation: Creating a Pro-survival and Anti-Inflammatory Phenotype in Lethal Hemorrhagic and Septic Shock. J Biomed Biotechnol: 2011; 2011 523481
35. Faraco G., Pittelli M., Cavone L., Fossati S., Porcu M., Mascagni P., Fossati G., Moroni F., Chiarugi A. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis: 2009; 36 269 279
36. Huang N., Katz J. P., Martin D. R., Wu G. D. Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine: 1997; 9 27 36
37. Kramer O. H., Gottlicher M., Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab: 2001; 12 294 300
38. Bhaumik D., Scott G. K., Schokrpur S., Patil C. K., Orjalo A. V., Rodier F., Lithgow G. J., Campisi J. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging: 2009; 1 402 411
39. Coppé J. P., Patil C. K., Rodier F., Sun Y., Muñoz D. P., Goldstein J., Nelson P. S., Desprez P. Y., Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol: 2008; 6 e301
40. Gan C. P., Hamid S., Hor S. Y., Zain R. B., Ismail S. M., Wan Mustafa W. M., Teo S. H., Saunders N., Cheong S. C. Valproic acid: Growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck: 2012; 34 344 353
41. Li X. N., Shu Q., Su JM F., Perlaky L., Blaney S. M., Lau C. C. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther: 2005; 4 1912 1922
42. Cowland J. B., Hother C., Gronbæk K. MicroRNAs and cancer. Apmis: 2007; 115 1090 1106
43. Sztajnkrycer M. D. Valproic acid toxicity: overview and management. Clin Toxicol: 2002; 40 789 801